Arcutis Biotherapeutics Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 07:13

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for t

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.